Clozapine, a fast-off-D2 antipsychotic

ACS Chemical Neuroscience

Volumn 5, Issue 1, 2014, Pages 24-29

  Seeman, Philip ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

5HT2A receptor; Dopamine; dopamine D2 receptor; psychosis

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; GLUTAMATE RECEPTOR; HALOPERIDOL; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR;

CHEMICAL STRUCTURE; CORPUS STRIATUM; DISSOCIATION; DISSOCIATION CONSTANT; HUMAN; PARKINSONISM; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CORPUS STRIATUM; HUMANS; MENTAL DISORDERS; PROTEIN BINDING; RECEPTORS, DOPAMINE D2;

EID: 84892693147     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400189s     Document Type: Review

References (47)

1. Hunziker, F., Fischer, E., and Schmutz, J. (1967) 11-Amino-5 H -dibenzo[ b, e ]-1,4-diazepine. 10. Mitteilung über siebengliedrige Heterocyclen Helv. Chim. Acta 50 (6) 1588-1599
2. Schmutz, J. (1975) Neuroleptic piperazinyl-dibenzo-azepines. Chemistry and structure-activity relationships Arzneimittelforschung 25 (5) 712-720
3. de Paulis, T., Betts, C. R., Smith, H. E., Mobley, P. L., Manier, D. H., and Sulser, F. (1981) Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain J. Med. Chem. 24 (9) 1021-1026
4. Bürki, H. R., Sayers, A. C., Ruch, W., and Asper, H. (1977) Effects of clozapine and other dibenzo-epines on central dopaminergic and cholinergic systems. Structure-activity relationships Arzneimittelforschung 27 (8) 1561-1565
5. Wenthur, C. J. and Lindsley, C. W. (2013) Classics in chemical neuroscience: Clozapine ACS Chem. Neurosci. 4, 1018-1025
6. Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., and Weiden, P. J. (1999) Antipsychotic-induced weight gain: A comprehensive research synthesis Am. J. Psychiatry 156 (11) 1686-1696
7. Meltzer, H. Y. (2012) Clozapine: Balancing safety with superior antipsychotic efficacy Clin. Schizophr. Relat. Psychoses 6 (3) 134-144
8. Kane, J., Honigfeld, G., Singer, J., and Meltzer, H. (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch. Gen. Psychiatry 45 (9) 789-796
9. Seeman, P., Chau-Wong, M., Tedesco, J., and Wong, K. (1975) Brain receptors for antipsychotic drugs and dopamine: Direct binding assays Proc. Natl. Acad. Sci. U.S.A. 72, 4376-4380
10. Seeman, P., Lee, T., Chau-Wong, M., and Wong, K. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors Nature 261, 717-719
11. Madras, B. K. (2013) History of the discovery of the antipsychotic dopamine D2 receptor: A basis for the dopamine hypothesis of schizophrenia J. Hist. Neurosci. 22 (1) 62-78
12. Su, T. P., Malhotra, A. K., Hadd, K., Breier, A., and Pickar, D. (1997) D2 dopamine receptor occupancy: A crossover comparison of risperidone with clozapine therapy in schizophrenic patients Arch. Gen. Psychiatry 54 (10) 972-973
13. Pickar, D. (1995) Prospects for pharmacotherapy of schizophrenia Lancet 345 (8949) 557-562
14. Ebdrup, B. H., Rasmussen, H., Arnt, J., and Glenthøj, B. (2011) Serotonin 2A receptor antagonists for treatment of schizophrenia Expert Opin. Invest. Drugs 20 (9) 1211-1223
15. Kapur, S. and Seeman, P. (2001) Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis Am. J. Psychiatry 158, 360-369
16. 2 receptor in schizophrenia Expert Opin. Ther. Targets 10 (4) 515-531
17. High receptors CNS Neurosci. Ther. 17 (2) 118-132
18. Seeman, P. and Van Tol, H. H. M. (1995) Deriving the therapeutic concentrations for clozapine and haloperidol: The apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand Eur. J. Pharmacol., Mol. Pharmacol. Sect. 291, 59-66
19. Seeman, P., Corbett, R., Nam, D., and Van Tol, H. H. M. (1996) Dopamine and serotonin receptors: Amino acid sequences and clinical role in neuroleptic parkinsonism Jpn. J. Pharmacol. 71, 187-204
20. Seeman, P. (2010) Dopamine D2 receptors as treatment targets in schizophrenia Clin. Schizophr. Relat. Psychoses 4 (1) 56-73
21. 3H-spiperone depend on tissue concentration: Analysis and examples J. Neurochem. 43, 221-235
22. i values J. Pharmacol. Exp. Ther. 251 (1) 238-246
23. Meltzer, H. Y., Li, Z., Kaneda, Y., and Ichikawa, J. (2003) Serotonin receptors: Their key role in drugs to treat schizophrenia Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27, 1159-1172
24. Meltzer, H. Y. (2012) Serotonergic mechanisms as targets for existing and novel antipsychotics Handb. Exp. Pharmacol. 212, 87-124
25. Kapur, S., McClelland, R. A., Vanderspeck, S. C., Wadenberg, M.-L. G., Baker, G., Nobrega, J., Zipursky, R., and Seeman, P. (2002) Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action Neuroreport 13 (6) 831-835
26. Seeman, P. (2002) Atypical antipsychotics: Mechanism of action Can. J. Psychiatry 47, 27-38
27. Kapur, S., Zipursky, R. B., and Remington, G. (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia Am. J. Psychiatry 156 (2) 286-293
28. Meltzer, H. Y., Elkis, H., Vanover, K., Weiner, D. M., van Kammen, D. P., Peters, P., and Hacksell, U. (2012) Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day Schizophr. Res. 141 (2-3) 144-152
29. Nordstrom, A. L., Mansson, M., Jovanovic, H., Karlsson, P., Halldin, C., Farde, L., Vanover, K. E., Hacksell, U., Brann, M. R., Davis, R. E., and Weiner, D. M. (2008) PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain Int. J. Neuropsychopharmacol. 11 (2) 163-171
30. 3H]idazoxan in rat brain J. Pharmacol. Exp. Ther. 241 (3) 1092-1098
31. McAllister, K. H. and Rey, B. (1999) Clozapine reversal of the deficits in coordinated movement induced by D2 receptor blockade does not depend upon antagonism of α2 adrenoceptors Naunyn-Schmiedeberg's Arch. Pharmacol. 360 (6) 603-608
32. Giannini, A. J., Nageotte, C., Loiselle, R. H., Malone, D. A., and Price, W. A. (1984) Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: Da-2 receptor specificity J. Toxicol., Clin. Toxicol. 22 (6) 573-579
33. Giannini, A. J., Underwood, N. A., and Condon, M. (2000) Acute ketamine intoxication treated by haloperidol: A preliminary study Am. J. Ther. 7, 389-391
34. Kinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., and Jarkova, N. (2011) A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia J. Clin. Psychopharmacol. 31, 349-355
35. Seeman, P. (2012) Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia" by Kinon et al J. Clin. Psychopharmacol. 32, 291-292
36. Seeman, P. and Tallerico, T. (1998) Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors Mol. Psychiatry 3, 123-134
37. Seeman, P. and Tallerico, T. (1999) Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon drug withdrawal of clozapine or quetiapine Am. J. Psychiatry 156, 876-884
38. Seeman, P. (2005) An update on fast-off-D2 atypical antipsychotics Am. J. Psychiatry 162, 1984-1985
39. Kapur, S., Zipursky, R., Jones, C., Shammi, C. S., Remington, G., and Seeman, P. (2000) A positron emission tomography study of quetiapine in schizophrenia-A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy Arch. Gen. Psychiatry 57, 553-559
40. Nordström, A. L., Farde, L., and Halldin, C. (1992) Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol Psychopharmacology (Berlin) 106 (4) 433-438
41. Tresadern, G., Bartolome, J. M., Macdonald, G. J., and Langlois, X. (2011) Molecular properties affecting fast dissociation from the D2 receptor Bioorg. Med. Chem. 19 (7) 2231-2241
42. Langlois, X., Megens, A., Lavreysen, H., Atack, J., Cik, M., te Riele, P., Peeters, L., Wouters, R., Vermeire, J., Hendrickx, H., Macdonald, G., and De Bruyn, M. (2012) Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia J. Pharmacol. Exp. Ther. 342 (1) 91-105
43. 2 receptor antagonists using an agonist-antagonist interaction model AAPS J. 15 (2) 533-541
44. 2 receptor antagonist in the treatment of acute exacerbation of schizophrenia Eur. Neuropsychopharmacol. 22 (10) 721-733
45. 11C]raclopride and positron emission tomography J. Psychopharmacol. 26 (8) 1128-1135
46. 3H] raclopride: Implications for positron emission tomography of the human brain Synapse 3, 96-97
47. Remington, G., Seeman, P., Feingold, A., Mann, S., Shammi, C., and Kapur, S. (2011) "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: A double-blind, placebo-controlled trial J. Clin. Psychiatry 72 (8) 1042-1048